These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

259 related items for PubMed ID: 7473582

  • 1. Thiopyranol[2,3,4-c,d]indoles as inhibitors of 5-lipoxygenase, 5-lipoxygenase-activating protein, and leukotriene C4 synthase.
    Hutchinson JH, Charleson S, Evans JF, Falgueyret JP, Hoogsteen K, Jones TR, Kargman S, Macdonald D, McFarlane CS, Nicholson DW.
    J Med Chem; 1995 Oct 27; 38(22):4538-47. PubMed ID: 7473582
    [Abstract] [Full Text] [Related]

  • 2. Thiopyrano[2,3,4-cd]indoles as 5-lipoxygenase inhibitors: synthesis, biological profile, and resolution of 2-[2-[1-(4-chlorobenzyl)-4-methyl-6-[(5-phenylpyridin-2-yl)methoxy]-4,5 -dihydro-1H-thiopyrano[2,3,4-cd]indol-2-yl]ethoxy]butanoic acid.
    Hutchinson JH, Riendeau D, Brideau C, Chan C, Falgueyret JP, Guay J, Jones TR, Lépine C, Macdonald D, McFarlane CS.
    J Med Chem; 1994 Apr 15; 37(8):1153-64. PubMed ID: 8164257
    [Abstract] [Full Text] [Related]

  • 3. Substituted thiopyrano[2,3,4-c,d]indoles as potent, selective, and orally active inhibitors of 5-lipoxygenase. Synthesis and biological evaluation of L-691,816.
    Hutchinson JH, Riendeau D, Brideau C, Chan C, Delorme D, Denis D, Falgueyret JP, Fortin R, Guay J, Hamel P.
    J Med Chem; 1993 Sep 17; 36(19):2771-87. PubMed ID: 8410991
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Pharmacological characterization of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103), a novel selective 5-lipoxygenase-activating protein inhibitor that reduces acute and chronic inflammation.
    Lorrain DS, Bain G, Correa LD, Chapman C, Broadhead AR, Santini AM, Prodanovich P, Darlington JV, Hutchinson JH, King C, Lee C, Baccei C, Li Y, Arruda JM, Evans JF.
    J Pharmacol Exp Ther; 2009 Dec 17; 331(3):1042-50. PubMed ID: 19749079
    [Abstract] [Full Text] [Related]

  • 11. Studies of the inhibitory activity of MK-0591 (3-[1-(4-chlorobenzyl)-3-(t-butylthio)-5-(quinolin-2-yl-methoxy)-indol- 2-yl]-2,2-dimethyl propanoic acid) on arachidonic acid metabolism in human phagocytes.
    Ménard L, Laviolette M, Borgeat P.
    Can J Physiol Pharmacol; 1992 Jun 17; 70(6):808-13. PubMed ID: 1423024
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Inhibition of antigen-induced contraction of guinea-pig airways by a leukotriene synthesis inhibitor, BAY x1005.
    Gardiner PJ, Cuthbert NJ, Francis HP, Fitzgerald MF, Thompson AM, Carpenter TG, Patel UP, Newton BB, Mohrs K, Müller-Peddinghaus R.
    Eur J Pharmacol; 1994 Jun 02; 258(1-2):95-102. PubMed ID: 7925604
    [Abstract] [Full Text] [Related]

  • 15. Kinetic mechanism of glutathione conjugation to leukotriene A4 by leukotriene C4 synthase.
    Gupta N, Gresser MJ, Ford-Hutchinson AW.
    Biochim Biophys Acta; 1998 Mar 30; 1391(2):157-68. PubMed ID: 9554994
    [Abstract] [Full Text] [Related]

  • 16. A new class of leukotriene biosynthesis inhibitor: the development of MK-0591.
    Prasit P, Belley M, Blouin M, Brideau C, Chan C, Charleson S, Evans JF, Frenette R, Gauthier JY, Guay J.
    J Lipid Mediat; 1993 Mar 30; 6(1-3):239-44. PubMed ID: 8357985
    [Abstract] [Full Text] [Related]

  • 17. Tepoxalin: a dual cyclooxygenase/5-lipoxygenase inhibitor of arachidonic acid metabolism with potent anti-inflammatory activity and a favorable gastrointestinal profile.
    Argentieri DC, Ritchie DM, Ferro MP, Kirchner T, Wachter MP, Anderson DW, Rosenthale ME, Capetola RJ.
    J Pharmacol Exp Ther; 1994 Dec 30; 271(3):1399-408. PubMed ID: 7996452
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. 5-lipoxygenase-activating protein inhibitors: development of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103).
    Hutchinson JH, Li Y, Arruda JM, Baccei C, Bain G, Chapman C, Correa L, Darlington J, King CD, Lee C, Lorrain D, Prodanovich P, Rong H, Santini A, Stock N, Prasit P, Evans JF.
    J Med Chem; 2009 Oct 08; 52(19):5803-15. PubMed ID: 19739647
    [Abstract] [Full Text] [Related]

  • 20. An experimental cell-based model for studying the cell biology and molecular pharmacology of 5-lipoxygenase-activating protein in leukotriene biosynthesis.
    Gerstmeier J, Weinigel C, Barz D, Werz O, Garscha U.
    Biochim Biophys Acta; 2014 Sep 08; 1840(9):2961-9. PubMed ID: 24905297
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.